ClinicalTrials.gg
Sign In
CompletedNCT03260751Updated May 9, 2019

Efficacy and Safety of Zingiber Officinale Roscoe Extract on Body Fat

An interventional study of Zingiber officinale Roscoe extract 200 mg and Placebo in Obesity, sponsored by Chonbuk National University Hospital. Completed at 1 site in South Korea. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-09.

Sponsored by Chonbuk National University Hospital · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Feb 2017, registered Aug 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Study summary

This study was conducted to investigate the effects of daily supplementation of Zingiber officinale Roscoe extract on body fat.

Read the detailed description

This study was a 12 weeks, randomized, double-blind, placebo-controlled human trial. Forty subjects were randomly divided into Zingiber officinale Roscoe extract 200 mg or placebo group. The investigators measured Body Fat Mass, Percent Body Fat, Fat Free Mass, weight, and body mass index.

02

Conditions studied

  • Obesity

Browse trials for

03

In context

Obesity

6,570 studies on the registry are indexed under Obesity; 1,718 are open to participants now.

This study's enrollment of 80 is close to the median of 77 across 5,084 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Chonbuk National University Hospital is the lead sponsor of 92 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age between 19 and 65 years,
  • BMI 25\~29.9 kg/m2
  • subjects giving written informed consent

Exclusion criteria

Exclusion Criteria:

  • Significant variation in weight(more 10%) in the past 3 months
  • Cardiovascular disease, e.g. arrhythmia, heart failure, myocardial infarction, and patient with pacemaker
  • History of disease that could interfere with the test products or impede their absorption, such as gastrointestinal disease or gastrointestinal surgery
  • Participation in any other clinical trials within past 2 months
  • Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study
  • Pregnancy or breast feeding etc,.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Zingiber officinale Roscoe extract 200 mg

    2 cap/day, 800 mg/cap for 12 weeks

    Dietary Supplement: Zingiber officinale Roscoe extract 200 mg

  • Placebo comparator
    Placebo

    Placebo for 12 weeks

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementZingiber officinale Roscoe extract 200 mg

    2 cap/day, 800 mg/cap for 12 weeks

  • Dietary supplementPlacebo

    Placebo for 12 weeks

06

What researchers measure

Primary outcomes

  1. Changes of body fat mass

    Body fat mass was measured in study baseline and 12 week

    Time frame: Baseline and 12 week

Secondary outcomes

  1. Changes of percent body fat

    Percent body fat was measured in study baseline and 12 week

    Time frame: Baseline and 12 week

  2. Changes of fat free mass

    Fat Free Mass was measured in study baseline and 12 week

    Time frame: Baseline and 12 week

  3. Changes of weight

    Weight was measured in study baseline and 12 week

    Time frame: Baseline and 12 week

  4. Changes of body mass index

    Body mass index was measured in study baseline and 12 week

    Time frame: Baseline and 12 week

07

Study locations

1 site
  • Clinical Trial Center for Functional Foods Chonbuk National University Hospital
    Jeonju, Jeollabuk-do 54907, South Korea
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Jan 2018, 11 months.

Of 2,253 non-industry interventional studies with no phase under Obesity, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's 11 months is below that.

Counting every sponsor, half of 2,351 studies reached it within 26 months; a quarter within 11 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2017
First posted
Aug 24, 2017
StartActual
Feb 3, 2017
Primary completionActual
Jan 29, 2018
CompletionActual
Jan 29, 2018
Last update
May 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03260751
Lead sponsor
Chonbuk National University Hospital
Responsible party
Soo-Wan Chae (Principal investigator, Clinical Trial Center for Functional Foods, Chonbuk National University Hospital) — Principal investigator
First posted
Aug 24, 2017
Start date
Feb 3, 2017
Primary completion
Jan 29, 2018
Completion
Jan 29, 2018
Last update
May 9, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Obesity →

Other studies from this sponsor

Chonbuk National University Hospital

Start the discussion